<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940922-1-00077</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=84 g=1 f=4 --> List of Subjects  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 54  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Clinical investigations, Financial disclosure, Reporting and recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 312  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Drugs, Exports, Imports, Investigations, Labeling, Medical research, Reporting and recordkeeping requirements, Safety.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 314  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Administrative practice and procedure, Confidential business information, Drugs, Reporting and recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 320  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Drugs, Reporting and Recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 330  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Over-the-counter drugs.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 601  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Biologics, Confidential business information.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 807  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Confidential business information, Medical devices, Reporting and recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 814  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Administrative practice and procedure, Confidential business information, Medical Devices, Medical Research, Reporting and recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 860  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Administrative practice and procedure, Medical devices. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=4 --> Therefore, under the Federal Food, Drug, and Cosmetic Act, it is proposed that 21 CFR chapter I be amended as follows:  <!-- PJG 0012 frnewline --> 1. New part 54 is added to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=4 --> PART 54_FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=4 --> Sec.  <!-- PJG 0012 frnewline --> 54.1&blank;Purpose.  <!-- PJG 0012 frnewline --> 54.2&blank;Definitions.  <!-- PJG 0012 frnewline --> 54.3&blank;Scope.  <!-- PJG 0012 frnewline --> 54.4&blank;Disclosure requirements.  <!-- PJG 0012 frnewline --> 54.5&blank;Agency evaluation of financial interests.  <!-- PJG 0012 frnewline --> 54.6&blank;Recordkeeping and record retention.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 201, 301, 501, 502, 503, 505, 506, 507, 510, 513&hyph;520, 701, 702, 703, 704, 705, 706, and 708 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 360, 360c&hyph;360j, 371, 372, 373, 374, 375, 376, and 379); sec. 351 of the Public Health Service Act (42 U.S.C. 262).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;54.1  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Purpose.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) The Food and Drug Administration (FDA) evaluates clinical studies submitted in marketing applications as required by law for new human drugs and biological products and marketing applications and reclassification petitions for medical devices.  <!-- PJG 0012 frnewline --> (b) The agency reviews data generated in these clinical studies to determine whether the applications are approvable under the statutory requirements. FDA may consider clinical studies inadequate and the data inadequate if, among other things, appropriate steps have not been taken in the design, conduct, reporting, and analysis of the studies to minimize bias. One potential source of bias in clinical studies is a financial interest of the clinical investigator in the outcome of the study, either because the amount of compensation the investigator receives may be influenced by the outcome of the study, or because the investigator has a financial interest in the product under study or in the sponsor of the marketing application. This section and conforming regulations require the sponsor of a marketing application that relies in part on clinical data to disclose certain financial arrangements between the sponsor and its clinical investigators and certain interests of the clinical investigators in the product or in the sponsor. FDA will use this information, in conjunction with information about the design and purpose of the study, as well as information obtained through on-site inspections, in the agency's assessment of the reliability of the data.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;54.2  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Definitions.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> For the purposes of this part:  <!-- PJG 0012 frnewline --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Compensation affected by the outcome of clinical studies  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> means compensation that could be higher for a favorable outcome than for an unfavorable outcome, such as compensation explicitly greater in the event of a favorable result, or compensation to the investigator in the form of an equity interest in the sponsor's company or in the form of compensation tied to sales of the product, such as a royalty interest.  <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Significant equity interest in the applicant means  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices, or any equity interest in a publicly traded corporation that exceeds 5 percent of total equity.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            